Literature DB >> 14636936

A pilot study of mifepristone in combination with sublingual or vaginal misoprostol for medical termination of pregnancy up to 63 days gestation.

H Hamoda1, P W Ashok, J Dow, G M M Flett, A Templeton.   

Abstract

Of the total women included in the study, 96 women chose to receive misoprostol 600 microg sublingually while 53 women received misoprostol 800 microg vaginally 36-48 h after receiving mifepristone 200 mg. Complete abortion occurred in 93 women (98.9%) in the sublingual and 51 women (96.2%) in the vaginal group (p = 0.27). The mean induction-to-abortion interval was 3.2 h (SD = 1.4) in the sublingual and 4.1 h (SD = 1.5) in the vaginal group (p = 0.02). The mean gestation at abortion in weeks was 7.1 (SD = 1.0) in the sublingual and 7.7 (SD = 1.3) in the vaginal group (p = 0.003). Women in the sublingual group experienced more vomiting (p = 0.03), diarrhea (p = 0.02) and unpleasant taste in their mouth (p = 0.0001) while those in the vaginal group experienced more headache (p = 0.002). Of women in the sublingual group, 77% were satisfied with the route of misoprostol administration compared to 68% in the vaginal group (p = 0.25). These findings now need to be assessed in the context of a randomized controlled trial.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14636936     DOI: 10.1016/j.contraception.2003.07.004

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  2 in total

1.  Prophylactic Pregabalin to Decrease Pain During Medication Abortion: A Randomized Controlled Trial.

Authors:  EmmaKate B Friedlander; Reni Soon; Jennifer Salcedo; James Davis; Mary Tschann; Bliss Kaneshiro
Journal:  Obstet Gynecol       Date:  2018-09       Impact factor: 7.661

2.  Comparison of two doses and two routes of administration of misoprostol after pre-treatment with mifepristone for early pregnancy termination.

Authors:  Helena von Hertzen; Gilda Piaggio; Lena Marions
Journal:  Reprod Health       Date:  2008-06-23       Impact factor: 3.223

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.